Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for treating locally advanced or metastatic, triple negative, PD-L1 positive breast cancer that has not been previously treated.
Topic is suspended
 
Status Suspended
Process STA 2018
ID number 2705

Provisional Schedule

Expected publication 17 November 2021

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
27 November 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab with paclitaxel for untreated unresectable advanced triple-negative breast cancer. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
27 November 2020 Suspended. Topic is suspended
06 July 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of Atezolizumab with paclitaxel for untreated unresectable advanced triple-negative breast cancer. Please note that following on from information received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early January 2021 when we will write to you about how you can get involved.
29 May 2020 - 29 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 January 2020 In progress. Referred September 23 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance